108 related articles for article (PubMed ID: 30431089)
1. VEGI174 protein and its functional domain peptides exert antitumour effects on renal cell carcinoma.
Zhao Q; Hong B; Liu T; Ji Y; Tang X; Gong K; Ye L; Yang Y; Zhang N
Int J Oncol; 2019 Jan; 54(1):390-398. PubMed ID: 30431089
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth inhibitor 174 and its functional domains inhibit epithelial-mesenchymal transition in renal cell carcinoma cells in vitro.
Zhang N; Hong B; Lian W; Zhou C; Chen S; Du X; Deng X; Duoerkun S; Li Q; Yang Y; Gong K
Int J Mol Med; 2017 Aug; 40(2):569-575. PubMed ID: 28656288
[TBL] [Abstract][Full Text] [Related]
3. Protein of Vascular Endothelial Growth Inhibitor 174 Inhibits Epithelial-Mesenchymal Transition in Renal Cell Carcinoma
Zhao Q; Deng X; Hong B; Wang F; Tang X; Yang Y; Gong K; Ye L; Jiang WG; Zhang N
Anticancer Res; 2017 Aug; 37(8):4269-4275. PubMed ID: 28739718
[TBL] [Abstract][Full Text] [Related]
4. Identification of Novel Proteins Interacting with Vascular Endothelial Growth Inhibitor 174 in Renal Cell Carcinoma.
Zhao Q; Kun D; Hong B; Deng X; Guo S; Tang X; Yang Y; Gong K; Li Q; Ye L; Jiang WG; Zhang N
Anticancer Res; 2017 Aug; 37(8):4379-4388. PubMed ID: 28739731
[TBL] [Abstract][Full Text] [Related]
5. The differential expression of vascular endothelial growth inhibitor isoforms, VEGI251, VEGI174 and VEGI192 in human clear-cell renal cell carcinoma.
Zhang N; Wu P; Wu L; Shayiremu D; Shan H; Ye L; Jiang WG; Gong K; Yang Y
Cancer Genomics Proteomics; 2013; 10(1):47-53. PubMed ID: 23382586
[TBL] [Abstract][Full Text] [Related]
6. Suppression of renal cell carcinoma growth in vivo by forced expression of vascular endothelial growth inhibitor.
Zhang N; Wu P; Shayiremu D; Wu L; Shan H; Ye L; Zhao X; Cai J; Jiang WG; Gong K; Yang Y
Int J Oncol; 2013 May; 42(5):1664-73. PubMed ID: 23545578
[TBL] [Abstract][Full Text] [Related]
7. Parthenolide inhibits the tumor characteristics of renal cell carcinoma.
Liu D; Han Y; Liu L; Ren X; Zhang H; Fan S; Qin T; Li L
Int J Oncol; 2021 Jan; 58(1):100-110. PubMed ID: 33367934
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
D'Amato C; Rosa R; Marciano R; D'Amato V; Formisano L; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fulciniti F; Cipolletta A; Bianco C; Ciardiello F; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Sep; 111(6):1168-79. PubMed ID: 25093491
[TBL] [Abstract][Full Text] [Related]
9. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
Deng W; Han W; Fan T; Wang X; Cheng Z; Wan B; Chen J
Biomed Pharmacother; 2018 Nov; 107():1505-1513. PubMed ID: 30257368
[TBL] [Abstract][Full Text] [Related]
10. VHL loss predicts response to Aurora kinase A inhibitor in renal cell carcinoma cells.
Ding XF; Zhou J; Chen G; Wu YL
Mol Med Rep; 2018 Jul; 18(1):1206-1210. PubMed ID: 29845253
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.
Damiano V; Rosa R; Formisano L; Nappi L; Gelardi T; Marciano R; Cozzolino I; Troncone G; Agrawal S; Veneziani BM; De Placido S; Bianco R; Tortora G
Br J Cancer; 2013 Apr; 108(8):1616-23. PubMed ID: 23571736
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic value of SC66 in human renal cell carcinoma cells.
Xu M; Wang Y; Zhou LN; Xu LJ; Jin ZC; Yang DR; Chen MB; Zhu J
Cell Death Dis; 2020 May; 11(5):353. PubMed ID: 32393791
[TBL] [Abstract][Full Text] [Related]
13. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.
Horiguchi A; Asano T; Kuroda K; Sato A; Asakuma J; Ito K; Hayakawa M; Sumitomo M; Asano T
Br J Cancer; 2010 May; 102(11):1592-9. PubMed ID: 20461084
[TBL] [Abstract][Full Text] [Related]
14. Antitumour and antiangiogenic activities of [Pt(O,O'-acac)(γ-acac)(DMS)] in a xenograft model of human renal cell carcinoma.
Muscella A; Vetrugno C; Biagioni F; Calabriso N; Calierno MT; Fornai F; De Pascali SA; Marsigliante S; Fanizzi FP
Br J Pharmacol; 2016 Sep; 173(17):2633-44. PubMed ID: 27351124
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of lncRNA CASC2 by microRNA-21 increases the proliferation and migration of renal cell carcinoma cells.
Cao Y; Xu R; Xu X; Zhou Y; Cui L; He X
Mol Med Rep; 2016 Jul; 14(1):1019-25. PubMed ID: 27222255
[TBL] [Abstract][Full Text] [Related]
16. UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.
Hao P; Kang B; Li Y; Hao W; Ma F
Mol Med Rep; 2019 Aug; 20(2):1212-1220. PubMed ID: 31173226
[TBL] [Abstract][Full Text] [Related]
17. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
[TBL] [Abstract][Full Text] [Related]
18. miR‑133b affects cell proliferation, invasion and chemosensitivity in renal cell carcinoma by inhibiting the ERK signaling pathway.
Xu Y; Ma Y; Liu XL; Gao SL
Mol Med Rep; 2020 Jul; 22(1):67-76. PubMed ID: 32377748
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressive microRNA‑138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma.
Yamasaki T; Seki N; Yamada Y; Yoshino H; Hidaka H; Chiyomaru T; Nohata N; Kinoshita T; Nakagawa M; Enokida H
Int J Oncol; 2012 Sep; 41(3):805-17. PubMed ID: 22766839
[TBL] [Abstract][Full Text] [Related]
20. BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma.
Wan P; Chen Z; Zhong W; Jiang H; Huang Z; Peng D; He Q; Chen N
Oncol Rep; 2020 Dec; 44(6):2475-2486. PubMed ID: 33125143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
